Cargando…

Intra-tumoral Heterogeneity of KRAS and BRAF Mutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample Testing

KRAS mutation status is established as a predictive biomarker of benefit from anti-EGFr therapies. Mutations are normally assessed using DNA extracted from one formalin-fixed, paraffin-embedded (FFPE) tumor block. We assessed heterogeneity of KRAS and BRAF mutation status intra-tumorally (multiple b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Richman, Susan D., Chambers, Philip, Seymour, Matthew T., Daly, Catherine, Grant, Sophie, Hemmings, Gemma, Quirke, Philip
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2011
Materias:	Other
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4605581/ https://www.ncbi.nlm.nih.gov/pubmed/21483104 http://dx.doi.org/10.3233/ACP-2011-0005

Ejemplares similares

KRAS, p53 and BRAF Gene Mutations and Aneuploidy in Sporadic Colorectal Cancer Progression
por: Calistri, Daniele, et al.
Publicado: (2006)

Duplex Reverse-Hybridization Assay for The Simultaneous Detection of KRAS/BRAF Mutations in FFPE-extracted Genomic DNA from Colorectal Cancer Specimens
por: Buxhofer-Ausch, Veronika, et al.
Publicado: (2013)

Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin‐based or irinotecan‐based therapy for colorectal cancer
por: Takahashi, Shin, et al.
Publicado: (2021)

KRAS, NRAS, BRAF mutation comparison of endoscopic and surgically removed primary CRC paired samples: is endoscopy biopsy material adequate for molecular evaluation?
por: Saridaki, Z, et al.
Publicado: (2015)

Neuroendocrine Differentiation in Sporadic CRC and Hereditary Nonpolyosis Colorectal Cancer
por: Sun, M. H.
Publicado: (2004)

KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants
por: Heublein, Sabine, et al.
Publicado: (2013)

Intra-patient heterogeneity of BRAF mutation status: fact or fiction?
por: Menzies, A M, et al.
Publicado: (2014)

The MalR type regulator AcrC is a transcriptional repressor of acarbose biosynthetic genes in Actinoplanes sp. SE50/110
por: Wolf, Timo, et al.
Publicado: (2017)

Reply: Intra-patient heterogeneity of BRAF mutation status: fact or fiction?
por: Heinzerling, L, et al.
Publicado: (2014)

Intra- and Inter-Tumor BRAF Heterogeneity in Acral Melanoma: An Immunohistochemical Analysis
por: Ito, Takamichi, et al.
Publicado: (2019)

CRC handbook of thermophysical and thermochemical data
por: Lide, David R, et al.
Publicado: (1994)

KRAS and BRAF genotyping of synchronous colorectal carcinomas
por: GIANNINI, RICCARDO, et al.
Publicado: (2014)

NUDT7 Loss Promotes Kras(G12D) CRC Development
por: Song, Jinsoo, et al.
Publicado: (2020)

BRAF in Papillary Thyroid Carcinoma
por: Lanzilotta, Salvatore Giovanni, et al.
Publicado: (2007)

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial
por: Adams, Richard, et al.
Publicado: (2017)

Coexistence of KRAS and BRAF Mutations in Colorectal Cancer: A Case Report Supporting The Concept of Tumoral Heterogeneity
por: Larki, Pegah, et al.
Publicado: (2017)

Intra-patient Heterogeneity of BRAF and NRAS Molecular Alterations in Primary Melanoma and Metastases
por: PELLEGRINI, Cristina, et al.
Publicado: (2020)

Detection of KRAS, NRAS and BRAF by mass spectrometry - a sensitive, reliable, fast and cost-effective technique
por: Kriegsmann, Mark, et al.
Publicado: (2015)

HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials
por: Richman, Susan D, et al.
Publicado: (2016)

BRAF, MEK, and EGFR Triplet Inhibitors as Salvage Therapy in BRAF-Mutated Metastatic Colorectal Cancer—A Case Series Study Target Therapy of BRAF-Mutated mCRC
por: Yeh, Jen-Hao, et al.
Publicado: (2021)

Frequent mutations of KRAS in addition to BRAF in colorectal serrated adenocarcinoma
por: Stefanius, Karoliina, et al.
Publicado: (2011)

EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas
por: BUJKO, MATEUSZ, et al.
Publicado: (2014)

Mitochondrial Respiration in KRAS and BRAF Mutated Colorectal Tumors and Polyps
por: Rebane-Klemm, Egle, et al.
Publicado: (2020)

KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma
por: Pasca, Sergiu, et al.
Publicado: (2019)

Intra- and Inter-Tumor Heterogeneity of BRAF(V600E)Mutations in Primary and Metastatic Melanoma
por: Yancovitz, Molly, et al.
Publicado: (2012)

Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial
por: Seymour, Matthew T, et al.
Publicado: (2013)

The relationships of OSBPL3 expression with KI-67 expression and KRAS mutations in CRC: implications for diagnosis and prognosis
por: Zhang, Min, et al.
Publicado: (2022)

α4-α5 Helices on Surface of KRAS Can Accommodate Small Compounds That Increase KRAS Signaling While Inducing CRC Cell Death
por: Abuasaker, Baraa, et al.
Publicado: (2023)

The relationship between the BRAF p.V600E mutation and a family history of CRC in the early-onset CRC cases from the Australasian Colon Cancer Family Study
por: Buchanan, DD, et al.
Publicado: (2012)

Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?
por: Yokota, Tomoya
Publicado: (2012)

KRAS and BRAF mutational status in colon cancer from Albanian patients
por: Martinetti, Daniela, et al.
Publicado: (2014)

KRAS and BRAF somatic mutations in colonic polyps and the risk of metachronous neoplasia
por: Juárez, Miriam, et al.
Publicado: (2017)

Evaluation of EGFR, KRAS and BRAF gene mutations in renal cell carcinoma
por: Bayrak, Omer, et al.
Publicado: (2014)

Integrating TYMS, KRAS and BRAF testing in patients with metastatic colorectal cancer
por: Ntavatzikos, Anastasios, et al.
Publicado: (2017)

BRAF and KRAS mutations in papillary thyroid carcinoma in the United Arab Emirates
por: Al-Salam, Suhail, et al.
Publicado: (2020)

Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab
por: Giampieri, Riccardo, et al.
Publicado: (2021)

Early changes in circulating tumor DNA (ctDNA) predict treatment response in metastatic KRAS-mutated colorectal cancer (mCRC) patients
por: Lavacchi, Daniele, et al.
Publicado: (2023)

Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab
por: Zhang, Hangyu, et al.
Publicado: (2020)

Breast Cancer Heterogeneity Examined by High-Sensitivity Quantification of PIK3CA, KRAS, HRAS, and BRAF Mutations in Normal Breast and Ductal Carcinomas()()
por: Myers, Meagan B., et al.
Publicado: (2016)

EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma
por: Szablewski, Vanessa, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_43v46tmbqbvk4fd2o2nar76plh